Page 9 - Flipbook

Keynote-564

• Question: Should patients with high risk features after

surgery receive adjuvant pembrolizumab?

• RCT

• 994 pts with high risk Clear cell RCC post nephrectomy

• T2G4/sarcomatoid, ≥T3, N1, M1 with NED

• Intervention: 1 year Pembro vs placebo

• Outcome: Disease-free survival (investigators assessment)